Daniel Heudobler

1.6k total citations
45 papers, 426 citations indexed

About

Daniel Heudobler is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Daniel Heudobler has authored 45 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Molecular Biology and 10 papers in Hematology. Recurrent topics in Daniel Heudobler's work include CAR-T cell therapy research (9 papers), Acute Myeloid Leukemia Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Daniel Heudobler is often cited by papers focused on CAR-T cell therapy research (9 papers), Acute Myeloid Leukemia Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Daniel Heudobler collaborates with scholars based in Germany, Italy and Netherlands. Daniel Heudobler's co-authors include Albrecht Reichle, Wolfgang Herr, Florian Lüke, Tobias Pukrop, Christopher Gerner, Martin Vogelhuber, Lina Ghibelli, Sebastian Klobuch, Dennis Christoph Harrer and Simone Thomas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Daniel Heudobler

41 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Heudobler Germany	13	188	185	87	70	67	45	426
Yanfeng Liu China	11	242 1.3×	163 0.9×	102 1.2×	56 0.8×	53 0.8×	41	486
Hidenori Kasahara Japan	9	203 1.1×	137 0.7×	46 0.5×	81 1.2×	54 0.8×	21	476
Ruirong Yuan United States	9	209 1.1×	204 1.1×	38 0.4×	76 1.1×	76 1.1×	11	470
Minjia Sheng China	8	178 0.9×	158 0.9×	41 0.5×	131 1.9×	77 1.1×	12	433
Bastien Kaniewski France	10	235 1.3×	102 0.6×	89 1.0×	66 0.9×	74 1.1×	12	429
Kathleen Dass United States	6	156 0.8×	136 0.7×	62 0.7×	39 0.6×	50 0.7×	17	458
Lillian Pliner United States	11	157 0.8×	149 0.8×	54 0.6×	47 0.7×	21 0.3×	15	359
Jelena Urosevic Spain	8	221 1.2×	227 1.2×	37 0.4×	57 0.8×	21 0.3×	10	462
Cuihong Wei Canada	8	118 0.6×	147 0.8×	22 0.3×	89 1.3×	90 1.3×	16	368
Rob C. M. de Jong Netherlands	11	287 1.5×	149 0.8×	63 0.7×	237 3.4×	71 1.1×	22	583

Countries citing papers authored by Daniel Heudobler

Since Specialization

Citations

This map shows the geographic impact of Daniel Heudobler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Heudobler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Heudobler more than expected).

Fields of papers citing papers by Daniel Heudobler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Heudobler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Heudobler. The network helps show where Daniel Heudobler may publish in the future.

Co-authorship network of co-authors of Daniel Heudobler

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Heudobler. A scholar is included among the top collaborators of Daniel Heudobler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Heudobler. Daniel Heudobler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, Albrecht Reichle, & Daniel Heudobler. (2026). Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. International Journal of Molecular Sciences. 27(2). 1067–1067.

Proescholdt, Martin, Karl-Michael Schebesch, Christian Doenitz, et al.. (2025). MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases. Translational Oncology. 60. 102480–102480. 1 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2025). MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck. Frontiers in Pharmacology. 16. 1553331–1553331. 1 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2024). Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. Frontiers in Oncology. 13. 1289222–1289222. 3 indexed citations

Mackensen, Andréas, Winfried Alsdorf, Daniel Heudobler, et al.. (2024). 611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors. Annals of Oncology. 35. S489–S490. 7 indexed citations

Wermke, Martin, Sebastian Ochsenreither, Manik Chatterjee, et al.. (2024). 1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation. Annals of Oncology. 35. S681–S682. 2 indexed citations

Heitmann, Jonas S., Juliane S. Walz, Helmut R. Salih, et al.. (2024). A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. Blood. 144(Supplement 1). 2883.1–2883.1. 1 indexed citations

Menhart, Karin, Dennis Christoph Harrer, W. Herr, et al.. (2024). Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab. Frontiers in Pharmacology. 15. 1334233–1334233. 1 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2023). Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance. Cancers. 16(1). 180–180. 5 indexed citations

10.

Fante, Matthias, Dennis Christoph Harrer, Florian Lüke, et al.. (2023). All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma. Frontiers in Oncology. 13. 1177330–1177330. 2 indexed citations

11.

Mackensen, Andréas, Winfried Alsdorf, Christian Koenecke, et al.. (2023). LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac). Annals of Oncology. 34. S1274–S1275. 1 indexed citations

12.

Blazquez, Raquel, Martin Proescholdt, Karl-Michael Schebesch, et al.. (2022). Breakouts—A Radiological Sign of Poor Prognosis in Patients With Brain Metastases. Frontiers in Oncology. 12. 849880–849880. 2 indexed citations

13.

Lüke, Florian, Dennis Christoph Harrer, Pan Pantziarka, et al.. (2022). Drug Repurposing by Tumor Tissue Editing. Frontiers in Oncology. 12. 900985–900985. 7 indexed citations

14.

Haanen, J.B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2021). LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors. Annals of Oncology. 32. S1392–S1392. 7 indexed citations

15.

Lüke, Florian, Dennis Christoph Harrer, Karin Menhart, et al.. (2021). Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease. Frontiers in Pharmacology. 12. 599561–599561. 11 indexed citations

16.

Lüke, Florian, Evelyn Orsó, Hendrik Poeck, et al.. (2020). Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells. SHILAP Revista de lepidopterología. 1(1). 376–383. 21 indexed citations

17.

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2019). Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction. Frontiers in Oncology. 9. 1408–1408. 15 indexed citations

18.

Janker, Lukas, Rupert L. Mayer, Andrea Bileck, et al.. (2019). Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia*. Molecular & Cellular Proteomics. 18(5). 936a–953. 33 indexed citations

19.

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2018). Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Frontiers in Pharmacology. 9. 1357–1357. 18 indexed citations

20.

Suleiman, Hani, Daniel Heudobler, Yangu Zhao, et al.. (2007). The podocyte-specific inactivation of Lmx1b, Ldb1 and E2a yields new insight into a transcriptional network in podocytes. Developmental Biology. 304(2). 701–712. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact